Copeptin and urine concentrating capacity predict kidney function decline in lithium-treated patients

Clicks: 13
ID: 331856
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #140 of 152 articles by views in nephrology dialysis transplantation

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 152 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction and Objectives A common early side effect of lithium treatment in bipolar disorder is a reduced urine concentrating capacity possibly progressing to arginine vasopressin (AVP) resistance (AVP-R), also known as lithium-induced nephrogenic diabetes insipidus (Li-NDI). Long term lithium therapy can also lead to chronic kidney disease (CKD) with kidney function decline. Due to lack of markers to identify Li-NDI, it is often overseen even though prevalence and impact on quality of life are substantial. Moreover, the correlation between reduction of urine concentrating capacity and CKD remains unclear. This study aims to identify markers for Li-NDI and future kidney function decline. Methods 98 patients treated with lithium underwent a desmopressin (DDAVP) test to determine maximal urine concentrating capacity (MUCC) after inclusion in 2012/2013. Plasma copeptin, urine biomarkers AQP-2, NAG, KIM-1, HFABP, NGAL and urine-to-plasma urea ratio (UPU) were measured. Long term follow-up data of kidney function decline during lithium therapy was collected of 93 out of 98 patients. Results Fifty patients (51%) had an mildly impaired MUCC (urine osmolality 600–800 mOsmol/kg), 16 patients (16%) a moderately decreased MUCC (300–600 mOsm/kg) and 1 patient (1%) a severely impaired MUCC (<300 mOsm/kg). Baseline eGFR, UPU, copeptin, KIM-1, HFABP and NGAL were significantly associated with MUCC when corrected for age, sex and eGFR (when appropriate) (eGFR: St. β=0.44, P ≤ 0.001, UPU: St. β=0.34, P ≤ 0.001; copeptin: St. β=-0.23, P = 0.02; KIM-1: St. β=-0.23, P = 0.02, HFABP: St. β=-0.21, P = 0.03) NGAL: St. β=-0.25, P = 0.02). eGFR, MUCC and copeptin at baseline were associated with kidney function during follow-up using mixed linear model analysis (eGFR: β=0.97 95%CI [0.88;1.06], P < 0.001; MUCC: β=0.05 95%CI[0.03;0.06], P < 0.001 and copeptin:-β=7.10 95%CI[-10.9;-3.28], P < 0.001). Conclusion Multiple biomarkers were identified to test for MUCC. Copeptin is particularly interesting as it was, together with MUCC, associated with future kidney function decline.
Reference Key
openalex_W7220897295 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Debbie Zittema, Merel van der Aa, Joan Doornebal, Elise M Bisseling, Ursula M. H. Klumpers, Ralph Kupka, Tom Nijenhuis, A P M Kerckhoffs
Are you one of these authors? Claim your profile
Journal nephrology dialysis transplantation
Year 2026
DOI
10.1093/ndt/gfag219
URL
https://doi.org/10.1093/ndt/gfag219
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.